DWTX
Dogwood Therapeutics, Inc.
$1.41
-0.03 (-2.08%)
At close · Jul 8
Market Cap
$47.42M
Shares
33,629,553
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$34.26M
-177.4%
FY2025
Diluted EPS
-$7.13
+43.1%
FY2025
Operating Cash Flow
-$15.62M
-77.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $133.25K | — | — | $150.9K | $67.48K | $5672 | -$384.22K | |
| $22.1M | $21.87M | $3.53M | $1.73M | $8.07M | $10.8M | $194.01K | |
| $6.52M | $6.1M | $8.7M | $3.72M | $4.25M | $4.85M | $9.81M | |
| $28.61M | $27.97M | $12.23M | $5.45M | $12.32M | $15.64M | $10.01M | |
| -$28.61M | -$27.97M | -$12.23M | -$5.45M | -$12.32M | -$15.64M | -$10.01M | |
| $327.6K | -$6.07M | -$122.98K | $150.9K | $67.48K | -$319.33K | -$341K | |
| -$28.29M | -$34.04M | -$12.35M | -$5.3M | -$12.25M | -$15.96M | -$10.35M | |
| — | $221.1K | -$503 | — | — | — | — | |
| -$28.32M | -$34.26M | -$12.35M | -$5.3M | -$12.25M | -$15.96M | -$10.35M | |
| -$28.32M | -$35.51M | -$12.86M | -$5.3M | — | — | — | |
| -$26.24M | -$30.98M | -$16.21M | -$5.3M | — | — | — | |
| USD/shares | — | -$7.13 | -$12.52 | -$7.05 | -$27.75 | -$48.00 | -$52.50 |
| USD/shares | — | -$7.13 | -$12.52 | -$7.05 | -$27.75 | -$48.00 | -$52.50 |
| shares | — | 4.98M | 1.03M | 751.07K | 442.8K | 333.17K | 197.08K |
| shares | — | 4.98M | 1.03M | 751.07K | 442.8K | 333.17K | 197.08K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
1.21×
Biotechnology median 7.68×